Glatiramer Acetate 40 mg/mL in Relapsing–Remitting Multiple Sclerosis: A Review
- 562 Downloads
Glatiramer acetate (Copaxone®) is a synthetic analogue of myelin basic protein, which is thought to be involved in the pathogenesis of multiple sclerosis (MS). The therapeutic effects of the drug in the treatment of MS are thought to be via immunomodulation and neuroprotection. Subcutaneous glatiramer acetate 20 mg/mL once daily is approved in several countries for the treatment of relapsing forms of MS. Recently, a high-concentration formulation of glatiramer acetate 40 mg/mL administered three times weekly was approved in the USA and several European countries in the same indication. This article reviews the efficacy and tolerability of the high-concentration regimen. In the randomized, phase III GALA study in patients with relapsing–remitting MS (RRMS), glatiramer acetate 40 mg/mL three times weekly reduced annualized relapse rates significantly more than placebo, and indirect comparisons indicate that the efficacy of the three-times-weekly regimen is similar to that of the 20 mg/mL once-daily regimen. Results of the randomized, phase IIIb GLACIER study in patients with RRMS demonstrated that the three-times-weekly regimen reduced the risk of injection-site reactions by 50 % and was associated with numerically greater patient convenience scores than the once-daily regimen. Thus, in the treatment of RRMS, glatiramer acetate 40 mg/mL three times weekly is effective and provides a better tolerated and possibly more convenient option than the once-daily regimen.
KeywordsExpand Disability Status Scale Glatiramer Acetate Glatiramer Clinically Isolate Syndrome Annualize Relapse Rate
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Kate McKeage is a salaried employee of Adis/Springer.
- 2.A consensus paper by the multiple sclerosis coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. 2014 July. http://www.mscare.org/?page=dmt. Accessed 26 Mar 2015.
- 10.Teva Pharmaceuticals USA Inc. Copaxone (glatiramer acetate injection): prescribing information. Philadelphia (PA): Teva Pharmaceuticals; 2014.Google Scholar
- 11.Medicines and Healthcare Products Regulatory Agency. Copaxone 40 mg/ml solution for injection: summary of product characteristics 2015. http://www.mhra.gov.uk/spc-pil/index.htm?prodName=COPAXONE. Accessed 26 Mar 2015.
- 13.Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49:290–7.PubMedCrossRefGoogle Scholar
- 15.Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903–14.PubMedCrossRefGoogle Scholar
- 19.Ford C, Ladkani D. Twenty years of continuous treatment of multiple sclerosis with glatiramer acetate 20 mg daily: long-term clinical results of the US open-label extension study [abstract plus poster P577]. Mult Scler. 2013;19(Suppl 1):242.Google Scholar
- 23.Khan O, Rieckmann P, Boyko A, et al. Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the glatiramer actetate low-frequency administration (GALA) open-label extension study [abstract no. P7.273]. In: American Academy of Neurology Annual Meeting. 2015.Google Scholar
- 25.Cutter G, Wolinsky JS, Comi G, et al. Comparable clinical and MRI efficacy of glatiramer acetate 40 mg/mL TIW and 20 mg/mL QD: results of a systematic review and meta-analysis [abstract no. P053]. Mult Scler. 2014;20(Suppl 1):90–1.Google Scholar
- 26.Cutter G, Wolinsky JS, Comi G, et al. Indirect comparison of glatiramer acetate 40 mg/mL TIW and 20 mg/mL QD dosing regimen effects on relapse rate: results of a predictive statistical model [abstract no. P100]. Mult Scler. 2014;20(Suppl 1):112.Google Scholar
- 27.Wolinsky JS, Dietrich DW, Borresen TE, et al. GLACIER: open-label, randomized safety/tolerability study of glatiramer acetate 40 mg/mL three times weekly versus 20 mg/mL daily in RRMS [abstract no. FC3.2]. Mult Scler. 2014;20(Suppl 1):43–4.Google Scholar
- 28.Wolinsky JS, Sidi Y, Steinerman JR, et al. Reduced frequency and severity of injection site reactions with glatiramer acetate 40 mg/mL three times weekly dosing [abstract no. P306 plus poster]. Mult Scler. 2014;20(Suppl 1):203–4.Google Scholar
- 29.Wynn D, Kolodny S, Rubinchick S, et al. Patient experience with glatiramer acetate 40 mg/1 mL three-times weekly treatment for relapsing–remitting multiple sclerosis: results from the GLACIER extension study [abstract no. P7.218]. In: American Academy of Neurology Annual Meeting. 2015.Google Scholar
- 30.Wolinsky JS, Borresen TE, Dietrich DW, et al. Convenience of glatiramer acetate 40 mg/mL three times weekly: evidence from the GLACIER study [abstract no. P080 plus poster]. Mult Scler. 2014;20(Suppl 1):103.Google Scholar
- 32.National Clinical Advisory Board of the National Multiple Sclerosis Society. Treatment recommendations for physicians: disease management consensus statement. 2008. http://www.nationalmssociety.org. Accessed 23 Mar 2015.
- 34.Di Battista G, Bertolotto A, Gasperini C, et al. Multiple sclerosis state of the art (SMART): a qualitative and quantitative analysis of therapy’s adherence, hospital reliability’s perception, and services provided quality. Mult Scler Int. 2014. doi: 10.1155/2014/752318.
- 40.Starossom SC, Veremeyko T, Dukhinova M, et al. Glatiramer acetate (Copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of Copaxone in targeting platelets during autoimmune neuroinflammation. PLoS One. 2014;9(5):e96256.PubMedCentralPubMedCrossRefGoogle Scholar